# Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

> **NCT06575127** · PHASE2 · RECRUITING · sponsor: **Al-Azhar University** · enrollment: 60 (estimated)

## Conditions studied

- Neoplasm Malignant
- Colon Cancer Stage 4

## Interventions

- **DRUG:** FOLFOXIRI Protocol

## Key facts

- **NCT ID:** NCT06575127
- **Lead sponsor:** Al-Azhar University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-17
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06575127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06575127, "Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06575127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*